(4-(3-chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone | 1355970-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (4-(3-chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone
• 英文别名: [4-(3-chloro-4-fluoroanilino)thieno[2,3-d]pyrimidin-6-yl]-(1H-indol-2-yl)methanone
• CAS: 1355970-09-0
• 化学式: C₂₁H₁₂ClFN₄OS
• 分子量: 422.87
• InChiKey: RJZRAQCJBYKZLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (4-(3-chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1-(phenylsulfonyl)-1H-indol-2-yl)methanone 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.5h， 生成 (4-(3-chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone
  参考文献：
  名称：

  Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones

  摘要：

  Several members of the quinazoline class of known tyrosine kinase inhibitors are approved anticancer agents, often showing selectivity for receptors of the HER/ErbB-family. Combining structural elements of this class with the bisindolylmethanone-structure led to a series of novel compounds. These compounds inhibited EGFR in the nanomolar range. Moreover, inhibition of EGFR autophosphorylation in intact A431 cells was shown, with IC50 values ranging form 0.3-1 mu M for compound 42, and 0.1-0.3 mu M for 45. In a panel of 42 human tumor cell lines the sensitivity profile of the novel compounds was shown to be similar to that of the quinazoline class of tyrosine kinase inhibitors lapatinib and erlotinib (Tarceva (R)). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.023

文献信息

• [EN] 4-AMINO-6-ARYL[2,3-D]PYRIMIDINES FOR THE INHIBITION OF EGFR TYROSINE KINASE<br/>[FR] 4-AMINO-6-ARYL[2,3-D]PYRIMIDINES POUR L'INHIBITION DE LA TYROSINE KINASE AU NIVEAU DE L'EGFR
  申请人：NORWEGIAN UNIV SCI & TECH NTNU

  公开号：WO2015000959A1

  公开（公告）日：2015-01-08

  This invention relates to certain new pyrrolo-, thieno-, and furo-[2,3- d]pyrimidine compounds, such as of general formula (I) These compounds are epidermal growth factor receptor tyrosine kinase inhibitors and therefore offer potential in the treatment of cancer.

  这项发明涉及某些新的吡咯基、噻吩基和呋喃基[2,3-d]嘧啶化合物，如一般式(I)所示。这些化合物是表皮生长因子受体酪氨酸激酶抑制剂，因此在癌症治疗中具有潜力。
• Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones
  作者：Thomas Beckers、Andreas Sellmer、Emerich Eichhorn、Herwig Pongratz、Christoph Schächtele、Frank Totzke、Gerhard Kelter、Rebekka Krumbach、Heinz-Herbert Fiebig、Frank-D. Böhmer、Siavosh Mahboobi

  DOI：10.1016/j.bmc.2011.11.023

  日期：2012.1

  Several members of the quinazoline class of known tyrosine kinase inhibitors are approved anticancer agents, often showing selectivity for receptors of the HER/ErbB-family. Combining structural elements of this class with the bisindolylmethanone-structure led to a series of novel compounds. These compounds inhibited EGFR in the nanomolar range. Moreover, inhibition of EGFR autophosphorylation in intact A431 cells was shown, with IC50 values ranging form 0.3-1 mu M for compound 42, and 0.1-0.3 mu M for 45. In a panel of 42 human tumor cell lines the sensitivity profile of the novel compounds was shown to be similar to that of the quinazoline class of tyrosine kinase inhibitors lapatinib and erlotinib (Tarceva (R)). (C) 2011 Elsevier Ltd. All rights reserved.